Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Says Zyrtec Is Prescription Antihistamine Least Impacted By OTCs

This article was originally published in The Tan Sheet

Executive Summary

Pfizer says Zyrtec (cetirizine HCl) has been hurt less than other prescription antihistamines by erosion in the OTC loratadine market

You may also be interested in...



OTC Zyrtec Could Be A Star If Ads Show Efficacy Over Claritin – UCSF’s Soller

A successful Rx-to-OTC switch of Pfizer's non-sedating antihistamine Zyrtec will depend largely on the marketer's ability to communicate the drug's advantages over Claritin through consumer marketing efforts, according to Bill Soller, PhD, executive director, Center for Consumer Self Care, UCSF School of Pharmacy

OTC Zyrtec Could Be A Star If Ads Show Efficacy Over Claritin – UCSF’s Soller

A successful Rx-to-OTC switch of Pfizer's non-sedating antihistamine Zyrtec will depend largely on the marketer's ability to communicate the drug's advantages over Claritin through consumer marketing efforts, according to Bill Soller, PhD, executive director, Center for Consumer Self Care, UCSF School of Pharmacy

OTC Zyrtec Could Be A Star If Ads Show Efficacy Over Claritin – UCSF’s Soller

A successful Rx-to-OTC switch of Pfizer's non-sedating antihistamine Zyrtec will depend largely on the marketer's ability to communicate the drug's advantages over Claritin through consumer marketing efforts, according to Bill Soller, PhD, executive director, Center for Consumer Self Care, UCSF School of Pharmacy

Topics

UsernamePublicRestriction

Register

PS097438

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel